Active Ingredient History
Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor. Sunitinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRa and PDGFRb), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony-stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib adverse events are considered somewhat manageable and the incidence of serious adverse events low. The most common adverse events associated with sunitinib therapy are fatigue, diarrhea, nausea, anorexia, hypertension, yellow skin discoloration, hand-foot skin reaction, and stomatitis. In the placebo-controlled Phase III GIST study, adverse events which occurred more often with sunitinib than placebo included diarrhea, anorexia, skin discoloration, mucositis/stomatitis, asthenia, altered taste, and constipation. Dose reductions were required in 50% of the patients studied in RCC in order to manage the significant toxicities of this agent. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acquired Immunodeficiency Syndrome (Phase 1)
Adenocarcinoma (Phase 2)
Adenoma, Islet Cell (Phase 2)
Adrenocortical Carcinoma (Phase 2)
Adult (Phase 2)
Anemia (Phase 1)
Angiogenesis Modulating Agents (Phase 2)
Antineoplastic Agents (Phase 2)
Ascites (Phase 2)
Astrocytoma (Phase 2)
Barrett Esophagus (Phase 2)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Biomarkers, Tumor (Phase 2)
Blood Pressure (Phase 1)
Brain Neoplasms (Phase 2/Phase 3)
Breast Neoplasms (Phase 4)
Breast Neoplasms, Male (Phase 2)
Burkitt Lymphoma (Phase 1)
Carcinoid Tumor (Phase 2)
Carcinoma (Phase 3)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Islet Cell (Phase 3)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Carcinoma, Verrucous (Phase 1)
Cholangiocarcinoma (Phase 2)
Choriocarcinoma (Phase 1)
Cognition Disorders (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 3)
Conjunctival Neoplasms (Phase 2)
Disease-Free Survival (Phase 2)
Endometrial Neoplasms (Phase 4)
Enzyme Inhibitors (Phase 3)
Ependymoma (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Female Urogenital Diseases (Phase 2)
Fibrosarcoma (Phase 2)
Germinoma (Phase 1)
Glioblastoma (Phase 2/Phase 3)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Graft vs Host Disease (Phase 1)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1)
Healthy Volunteers (Phase 1)
Hemangioblastoma (Phase 2)
Hemangiopericytoma (Phase 2)
Hemorrhagic Fever, Ebola (Phase 1/Phase 2)
Histiocytoma, Malignant Fibrous (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 1)
HIV Infections (Phase 1)
Hodgkin Disease (Phase 1)
Hormones (Phase 2)
Immune Checkpoint Inhibitors (Phase 2)
Immunoglobulin Light-chain Amyloidosis (Phase 1)
Immunoglobulin Light Chains (Phase 1)
Inflammatory Breast Neoplasms (Phase 2)
Intestinal Neoplasms (Phase 4)
Intraocular Lymphoma (Phase 1)
Kidney Diseases (Phase 3)
Kidney Neoplasms (Phase 3)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 2)
Leukemia, Eosinophilic, Acute (Phase 1)
Leukemia, Hairy Cell (Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 1)
Leukemia, Mast-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Neutrophilic, Chronic (Phase 1)
Leukemia, Prolymphocytic (Phase 2)
Liposarcoma (Phase 2)
Liver Neoplasms (Phase 2/Phase 3)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, AIDS-Related (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 1)
Lymphomatoid Granulomatosis (Phase 1)
Macular Degeneration (Phase 1/Phase 2)
Macular Edema (Phase 2)
Male Urogenital Diseases (Phase 2)
Melanoma (Phase 2)
Meningioma (Phase 2)
Mesothelioma (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 2/Phase 3)
Neoplasms ()
Neoplasms by Histologic Type (Phase 1/Phase 2)
Neoplasms by Site (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplasms, Hormone-Dependent (Phase 2)
Neoplasms, Plasma Cell (Phase 1)
Nervous System Neoplasms (Phase 1)
Neuroendocrine Tumors (Phase 2)
Neurofibroma (Phase 2)
Neurofibroma, Plexiform (Phase 2)
Neurofibromatoses (Phase 2)
Oligodendroglioma (Phase 2)
Osteosarcoma (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 4)
Palliative Care (Phase 2)
Pancreatic Neoplasms (Phase 4)
Paraganglioma (Phase 2)
Pelvic Neoplasms (Phase 1)
Pheochromocytoma (Phase 2)
Plasmacytoma (Phase 1)
Polycythemia Vera (Phase 1)
Primary Myelofibrosis (Phase 2)
Prostatectomy (Phase 2)
Prostatic Neoplasms (Phase 3)
Protein Kinase Inhibitors (Phase 3)
Retinal Diseases (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Alveolar Soft Part (Phase 2)
Sarcoma, Kaposi (Phase 2)
Sezary Syndrome (Phase 1)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Sunitinib (Phase 2)
Survival Rate (Phase 2)
Teratoma (Phase 2)
Testicular Neoplasms (Phase 2)
Therapeutic Equivalency (Phase 1)
Thoracic Neoplasms (Phase 1)
Thrombocythemia, Essential (Phase 1)
Thymoma (Phase 2)
Thymus Neoplasms (Phase 2)
Thyroid Cancer, Papillary (Phase 2)
Thyroid Neoplasms (Phase 4)
Tongue Neoplasms (Phase 1)
Transplantation (Phase 1)
Urethral Neoplasms (Phase 2)
Urinary Bladder (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Urogenital Diseases (Phase 2)
Urogenital Neoplasms (Phase 2)
Urologic Diseases (Phase 2)
Urologic Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
von Hippel-Lindau Disease (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
